News for Novavax, Inc. (NVAX)

Novavax, Inc. (NASDAQ:NVAX) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly -...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

Health and Human Services Secretary Robert F. Kennedy Jr.’s decision to dismiss all 17 members of the ACIP has triggered a decline in shares of pharmaceutical companies like Novavax (NVAX), Pfizer (PFE), and Merck (MRK) in after-hours trading. Kennedy’s overhaul, aimed at restoring public trust in vaccine science, raises concerns…

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) has experienced significant bullish options activity, with 15,477 call contracts traded, surpassing the expected volume by 10%. The implied volat

Summary Novavax Inc (NVAX), a biotechnology company known for its innovative vaccine solutions, announced on May 29, 2025, that it will participate in two signi

PR NewswireGAITHERSBURG, Md., May 29, 2025 GAITHERSBURG, Md., May 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will partic

Novavax (NVAX) to feature at Jefferies and Goldman Sachs investor conferences in June 2025. Live webcasts of events available, with replays accessible f

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Market Analysis by covering: S&P 500, Novavax Inc, Sanofi ADR, Novo Nordisk A/S. Read 's Market Analysis on Investing.com

On May 20, BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of […]

Novavax secures full FDA approval for NUVAXOVID, unlocking a $175M Sanofi payment.

The U.S. stock market took a breather on Tuesday, May 20, 2025, as investors reassessed whether the recent rally has outpaced economic fundamentals. The

U.S. stock futures were slightly lower on Tuesday after ending largely flat on Monday. Futures of major benchmark indices were trading lower in premarket.

The CNN Money Fear and Greed index showed some decline in the overall market sentiment, while the index remained in the “Greed” zone on Monday. U.S. stocks...

After recovering from an initial jolt, U.S. stocks drifted through quiet trading following the latest reminder that the U.S. government may be hurtling toward an unsustainable mountain of debt.

The S&P 500 eked out a gain of 0.1% on Monday, May 19, 2025, as investors weighed the implications of Moody's downgrading its U.S. credit rating.

The U.S. Food and Drug Administration has approved Nuvaxovid, a vaccine developed for the prevention of COVID-19 in adults 65 and over, as well as individuals a

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday. The Dow traded up 0.40% to 42,825.71 while t...